ARS Pharmaceuticals, Inc. Research and Development Expense
ARS Pharmaceuticals, Inc. (SPRY) reported Research and Development Expense of $4.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $4.70M, a 16.43% increase year-over-year.
- ARS Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $4.34M, a 46.88% increase year-over-year.
- ARS Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $3.44M, a 13.74% increase year-over-year.
- ARS Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $2.75M, a 37.80% decline year-over-year.
- ARS Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $13.18M, a 32.68% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $19.58M, a 3.38% decline from fiscal 2023.
- ARS Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $20.27M, a 10.29% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $18.38M, a 9.36% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.70M 10-Q · filed 2026-08-13 | $9.03M 10-Q · filed 2026-08-13 | $12.48M derived: sum of 3 quarters · filed 2026-08-13 | $15.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $4.34M 10-Q · filed 2026-05-15 | $7.78M derived: sum of 2 quarters · filed 2026-05-15 | $10.53M derived: sum of 3 quarters · filed 2026-05-15 | $14.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.19M derived: sum of 2 quarters · filed 2026-03-09 | $10.23M derived: sum of 3 quarters · filed 2026-08-13 | $13.18M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $2.75M 10-Q · filed 2025-11-10 | $6.79M derived: sum of 2 quarters · filed 2026-08-13 | $9.74M 10-Q · filed 2025-11-10 | $12.77M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $4.04M 10-Q · filed 2026-08-13 | $6.99M 10-Q · filed 2026-08-13 | $10.01M derived: sum of 3 quarters · filed 2026-08-13 | $14.44M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.95M 10-Q · filed 2026-05-15 | $5.98M derived: sum of 2 quarters · filed 2026-05-15 | $10.40M derived: sum of 3 quarters · filed 2026-05-15 | $17.30M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.45M derived: sum of 2 quarters · filed 2026-03-09 | $14.35M derived: sum of 3 quarters · filed 2026-03-09 | $19.58M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $4.42M 10-Q · filed 2025-11-10 | $11.32M derived: sum of 2 quarters · filed 2025-11-10 | $16.55M 10-Q · filed 2025-11-10 | $19.96M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $6.90M 10-Q · filed 2025-08-13 | $12.13M 10-Q · filed 2025-08-13 | $15.53M derived: sum of 3 quarters · filed 2025-08-13 | $18.54M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $5.23M 10-Q · filed 2025-05-14 | $8.64M derived: sum of 2 quarters · filed 2025-05-14 | $11.64M derived: sum of 3 quarters · filed 2025-05-14 | $18.95M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $6.41M derived: sum of 2 quarters · filed 2025-03-20 | $13.71M derived: sum of 3 quarters · filed 2025-03-20 | $20.27M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $3.00M 10-Q · filed 2024-11-13 | $10.31M derived: sum of 2 quarters · filed 2024-11-13 | $16.86M 10-Q · filed 2024-11-13 | $21.57M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $7.31M 10-Q · filed 2024-08-06 | $13.86M 10-Q · filed 2024-08-06 | $18.57M derived: sum of 3 quarters · filed 2024-08-06 | $22.46M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $6.55M 10-Q · filed 2024-05-09 | $11.26M derived: sum of 2 quarters · filed 2024-05-09 | $15.15M derived: sum of 3 quarters · filed 2024-05-09 | $19.50M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $8.60M derived: sum of 2 quarters · filed 2024-03-21 | $12.95M derived: sum of 3 quarters · filed 2024-03-21 | $18.38M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $3.89M 10-Q · filed 2023-11-09 | $8.36M 10-Q · filed 2022-11-02 | $8.24M derived: sum of 2 quarters · filed 2023-11-09 | $13.67M 10-Q · filed 2023-11-09 | $37.51M 10-Q · filed 2022-11-02 | -$11.69M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $4.35M 10-Q · filed 2023-08-10 | $12.24M 10-Q · filed 2022-08-11 | $9.77M 10-Q · filed 2023-08-10 | $29.14M 10-Q · filed 2022-08-11 | -$15.58M derived: sum of 3 quarters · filed 2023-08-10 | $57.00K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $5.42M 10-Q · filed 2023-05-15 | $16.90M 10-Q · filed 2022-05-12 | -$19.93M derived: sum of 2 quarters · filed 2023-05-15 | -$4.29M derived: sum of 3 quarters · filed 2023-05-15 | $13.46M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$25.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$9.72M derived: sum of 2 quarters · filed 2023-03-23 | $8.03M derived: sum of 3 quarters · filed 2023-03-23 | $20.27M 10-K · filed 2023-03-23 | $61.50M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $15.64M 10-Q · filed 2022-11-02 | $33.39M derived: sum of 2 quarters · filed 2022-11-02 | $45.63M 10-Q · filed 2022-11-02 | $54.47M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $17.75M 10-Q · filed 2022-08-11 | $29.99M 10-Q · filed 2022-08-11 | $38.83M derived: sum of 3 quarters · filed 2022-08-11 | $45.02M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $12.24M 10-Q · filed 2022-05-12 | $21.08M derived: sum of 2 quarters · filed 2022-05-12 | $27.28M derived: sum of 3 quarters · filed 2022-05-12 | $32.40M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $8.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $15.04M derived: sum of 2 quarters · filed 2022-03-31 | $20.16M derived: sum of 3 quarters · filed 2022-03-31 | $24.58M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $6.20M 10-Q · filed 2021-11-10 | $11.33M derived: sum of 2 quarters · filed 2021-11-10 | $15.74M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $5.13M 10-Q · filed 2021-08-12 | $9.54M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $4.41M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |